ReNeuron Outlines First-To-Market Plans For Stroke Disability Cell Therapy
Executive Summary
ReNeuron has high hopes of being the first to reach the US market with a novel stem cell therapy for use in patients with disabilities caused by stroke – CEO Olav Hellebø outlines the company's plans for Phase III and eventual commercialization.
You may also be interested in...
Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.
ReNeuron Stroke Stem Cell Therapy Advances
Encouraging early data from a Phase II trial of ReNeuron’s stem cell therapy CTX are adding to the evidence that it can improve patients with stroke disability, setting the stage for a pivotal trial next year.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.